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ABSTRACT
Pilocytic astrocytoma (PA) is the most common brain tumor in children but is 
rare in adults, and hence poorly studied in this age group. We investigated 222 PA and 
report increased aneuploidy in older patients. Aneuploid genomes were identified in 
45% of adult compared with 17% of pediatric PA. Gains were non-random, favoring 
chromosomes 5, 7, 6 and 11 in order of frequency, and preferentially affecting non-
cerebellar PA and tumors with BRAF V600E mutations and not with KIAA1549-BRAF 
fusions or FGFR1 mutations. Aneuploid PA differentially expressed genes involved in 
CNS development, the unfolded protein response, and regulators of genomic stability 
and the cell cycle (MDM2, PLK2), whose correlated programs were overexpressed 
specifically in aneuploid PA compared to other glial tumors. Thus, convergence of 
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INTRODUCTION
Pilocytic astrocytoma (PA) is a World Health 
Organization (WHO) grade I astrocytoma and the most 
common pediatric brain tumor [1, 2]. These tumors 
generally have an excellent prognosis and limited 
morbidity when amenable to gross total surgical 
resection [2, 3], with the highest age-adjusted incidence 
rate occurring in children between 0-19 years old when 
assessed across the lifespan [4]. In children, PAs most 
commonly occur in the cerebellum, and with decreasing 
frequency in other more surgically challenging brain 
locations including the optic pathway, thalamus, 
brainstem, spinal cord and cerebral hemispheres [5]. In 
adults, the reverse gradient for location is observed, and 
the low incidence of PA largely contributes to the relative 
lack of molecular investigations in this setting [5].
Recent genomic studies have shown that, in 
children, virtually all PAs can be categorized as harboring 
an alteration leading to constitutive activation of the 
MAPK pathway. The most common genetic alteration 
(~65%) is a tandem duplication at 7q34 creating an in-
frame fusion gene between BRAF and KIAA1549 [6-9]. 
Other alterations of the pathway include RAF-family 
fusions [7, 10], BRAF V600E mutation [11], germline NF1 
alterations (reviewed in [8]), and fibroblast growth factor 
receptor 1 (FGFR1) and NTRK-family alterations [9, 12]. 
In contrast, lower frequencies of RAF fusion transcripts 
have been reported in adult PAs [13]. Importantly, 50-
60% of PA in patients over the age of 20 years lacked 
a KIAA1549:BRAF fusion, BRAF V600E mutation or 
FGFR1 mutation [14]. This suggests that these tumors 
may harbor some of the rarer MAPK pathway alterations, 
or that other putative driver alterations or programs may 
additionally contribute to the molecular landscape of adult 
PA.
Whole-chromosomal copy number gains have 
been reported in a small cohort of 44 PA analyzed using 
array-based comparative genomic hybridization (aCGH) 
and seemed to favor older patients [15]. The prevalence, 
relation to patient age and significance of this phenotype 
as well as its relation to BRAF and MAPK alterations and 
possible underlying mechanisms remain, however, largely 
uncharacterized. As such, we analyzed a large combined 
dataset of 222 adult and pediatric PAs with whole-
chromosomal copy number data, including tumors from 
previously published aCGH and SNP array studies [6, 7, 
15-17]. We show that aneuploidy is a common feature 
of the genomes of adult PA, affecting 45% of tumors in 
this age range. This is a non-random process that favors 
gains but not losses, specifically in chromosomes 5, 7, 6 
and 11. It is strongly associated to non-cerebellar regions, 
which are less amenable to gross-total surgical resection, 
and to tumors harboring BRAF V600E mutation, which 
may be one of the molecular drivers of this phenotype. 
Pathways favoring aneuploidy are differentially regulated 
in adult PA, with many expression changes mapping to 
chromosome 5. This includes central nervous system 
(CNS) developmental pathways, unfolded protein response 
pathways and the cell cycle, including overexpression of 
MDM2 and PLK2, and specific gene expression signatures 
we identify to be strongly correlated with aneuploid PA. 
Furthermore, our findings suggest a link between aging 
and the physiological non-random aneuploidy which 
occurs in the brain and may predispose to this brain tumor. 
RESULTS
Non-random aneuploidy characterizes adult PA 
tumors arising throughout the CNS
We combined published datasets of whole-
chromosomal copy number analyses of PA tumors 
[6, 7, 15-17] with newly-derived profiles from DNA 
methylation data [10] as well as newly-analyzed tumor 
samples, and assembled copy number data for a combined 
series of 222 PAs (n = 44 adult; n = 178 pediatric). In 
our combined dataset, whole chromosomal gain in at 
least one chromosome was common, occurring in 22.5% 
(50/222) tumors overall (Figure 1a-1d; Supplementary 
Table 1). This aneuploidy was present in PA tumors 
occurring throughout the central nervous system 
(CNS), with a notable fraction occurring in surgically 
challenging areas such as the thalamus, hypothalamus, 
optic pathway, brainstem, 4th ventricle and spinal 
cord (Figure 1b). Aneuploidy tended to favor tumors 
occurring in non-cerebellar areas when compared with 
the location distribution of the euploid cohort, a trend 
which approached statistical significance (P = 0.0552; 
Fisher’s Exact Test). Aneuploidy was significantly more 
common in the adult PA subset (20/44, 45% vs. 30/178, 
17%; P = 0.0002; Fisher’s Exact Test) (Figure 1c) with 
the average age at diagnosis of patients with aneuploid 
PA tumors being about 10 years older than those with 
euploid tumors (19.5+/-2.1 years, compared to 9.9+/-
0.8 years, respectively; P < 0.0001; unpaired, two-
tailed t-test) (Figure 1d). The frequency of individual 
chromosomes affected demonstrated a specific pattern 
across the 50 aneuploid PAs, with the most commonly 
altered chromosomes in order of frequency being 
chromosomes 5, 7, 6 and 11, in keeping with previous 
findings [15]. These four chromosomes were statistically 
over-represented in overall events among the aneuploid 
tumors (P < 0.0001). In addition, chromosomes 1, 2, 3, 13, 
pathways affecting the cell cycle and genomic stability may favor aneuploidy in PA, possibly 
representing an additional molecular driver in older patients with this brain tumor.
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14 16, 17, 19 and 22 were significantly under-represented 
across the background of all changes (P < 0.05) (Figure 
1a). Aneuploidy did not appear to correlate with different 
progression-free survival (PFS) profiles through Kaplan-
Meier analysis (Supplementary Figure 3).
Aneuploidy and MAPK alterations in PA
By integrating aneuploidy and BRAF fusion status, 
we determined that tumors wild-type for BRAF fusion 
demonstrated an increased rate of aneuploidy (36%, 23/64 
vs 18%, 27/150; P = 0.0076; Fisher’s Exact Test) (Figure 
2a). Conversely, an increased frequency of aneuploidy is 
seen in tumors harboring BRAF mutations (53%, 8/15 vs 
20%, 32/127; P = 0.0074; Fisher’s exact test) (Figure 2b). 
Aneuploidy did not correlate significantly with FGFR1 
mutation status (P = 0.68; Fisher’s Exact Test). Using 
the R2 microarray analysis and visualization platform 
(http://r2.amc.nl), we identified differential expression of 
558 genes (FDR < 0.001, ANOVA) between euploid (n 
= 93) and aneuploid tumors (n = 29) (Figure 2c). Other 
comparisons demonstrated fewer genes differentially 
regulated at FDR < 0.001, including BRAF fusion 
positive vs negative (29 genes), BRAF mutation positive 
vs negative (216 genes) and age group categories (462 
genes), demonstrating a strong effect of aneuploidy on 
global gene expression patterns in PA (Figure 2c). 
Pathways aberrantly regulated in aneuploid 
tumors
Gene Ontology (GO) analysis of the 558 genes 
differentially regulated between euploid and aneuploid 
tumors revealed significance of molecular pathways 
Figure 1: Characterization of aneuploidy observed in pilocytic astrocytoma. a., Gains in 50 aneuploid PA samples (upper 
panel), frequency of specific gains, and significance (P < 0.05; Fisher’s Exact Test; lower panel). b., Neuroanatomical distribution of 
aneuploid PA tumors favors non-cerebellar areas. c., Increased aneuploidy observed amongst adult PA tumors (P = 0.0002; Fisher’s Exact 
Test). d., Age of patients with aneuploid and euploid PA tumors (P < 0.0001; unpaired two-tailed t-test).
Oncotarget4www.impactjournals.com/oncotarget
including GO terms such as CNS development (GO: 
7417), cell cycle arrest (GO: 7050), G1/S transition 
of the mitotic cell cycle (GO: 82) and unfolded protein 
binding (GO: 51082) (Figure 3a). Mapping of these 
558 genes to their respective chromosomal locations 
revealed enrichment (over-representation of differentially 
expressed genes) on chromosomes 5 and 7, and under-
representation of chromosomes 1, 10, 14, 17 and 19 
(Figure 3b), mirroring the relative frequency of gains of 
these chromosomes seen in our cohort. Candidate genes 
significantly de-regulated between aneuploid and euploid 
PA tumors included MDM2 (Figure 3c), encoding the E3 
ubiquitin ligase MDM2, and polo-like kinase 2 (PLK2) 
(Figure 3d). These genes were also strongly correlated 
with each other in the 122 PA tumors with available gene 
expression and ploidy status (P = 0.01, Figure 3e).
MDM2 is highly expressed in aneuploid PA
Utilizing the R2 database tool, we sought to 
investigate MDM2 expression comparatively across PA, 
as well as in other gliomas and control brain samples. 
Across multiple gene expression datasets including PA, 
adult glioblastoma (GBM), pediatric high-grade glioma 
(pHGG), diffuse intrinsic pontine glioma (DIPG), 
ependymoma (EP) and normal brain (NB) and cerebellum 
(CB) samples, aneuploid PA tumors demonstrated the 
highest levels of MDM2 expression (Figure 4a). Further 
dissection of MDM2 expression within the PA dataset with 
available clinical and molecular variables revealed a strong 
association of MDM2 over-expression in adult PA samples 
(P = 1.1x10-4; ANOVA) (Figure 4b), tumors wild-type 
for BRAF fusion (P = 8.0x10-6 ANOVA) (Figure 4c) and 
tumors harboring BRAF mutations (P = 9.3x10-7; ANOVA) 
(Figure 4d), mirroring our findings as to the association 
of these factors with aneuploidy. Even slight elevations 
in MDM2 expression have been reported to accelerate 
tumorigenesis (e.g. in association with the MDM2 SNP 
309 [18, 19]). Manual curation of DNA copy number 
profiles revealed PA genomes largely deficient in focal 
copy number alterations other than BRAF duplication and 
whole-chromosomal aneuploidy, suggesting mechanisms 
other than MDM2 genomic amplification as causal for 
MDM2 overexpression (data not shown). Consequently, 
we investigated whether this MDM2 over-expression is 
Figure 2: Aneuploidy is differentially associated with prominent MAPK alterations in PA with a strong effect on global 
gene expression. a., Frequency of aneuploidy within BRAF fusion (P = 0.0076; Fisher’s Exact Test) a. and BRAF mutation (P = 0.0074; 
Fisher’s Exact Test) b. subsets of PA tumors. c., Strong effect of aneuploidy on global gene expression in PA at FDR < 0.001.
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associated with the well-characterized promoter SNP 
309 of MDM2, which influences expression from the 
P2 promoter of MDM2 (Supplementary Figure 1a), 
we sequenced this SNP in 201 tumors and looked for 
correlations with MDM2 expression and ploidy status 
where available (Supplementary Table 1, Supplementary 
Figure 1b-1e). SNP 309 TT, TG and GG genotypes were 
differentially associated with aneuploidy, although this did 
not reach statistical significance (P = 0.0926; Chi-square 
test). SNP 309 status also did not consistently correlate 
with overall levels of MDM2 expression either by array-
based analysis or in a small validation cohort of tumor 
RNA samples using qPCR (Supplementary Figure 1c-
1d). No differences of MDM2 P1 and P2 promoter usage, 
which is affected by SNP 309 (reviewed in [20]), were 
observed in exon-level RNA-sequencing analysis using 
a previously reported dataset [9] (Supplementary Figure 
1e), suggesting other mechanisms upregulate MDM2 in 
aneuploid PA tumors (Supplementary Figure 1a). 
MDM2-correlated gene signatures are robust in 
pilocytic astrocytoma
 Utilizing the R2 database tool, we analyzed 
genome-wide gene expression correlations with MDM2 
(absolute correlation, FDR < 0.001) in PA and other 
gliomas to determine candidate programs that may 
lead to aneuploidy in these tumors. Several hundred 
genes correlated very strongly with the expression of 
MDM2 within a PA dataset of 122 tumors profiled for 
ploidy status (741 genes at FDR < 0.001). Interestingly, 
in other publicly available glioma datasets including 
pediatric high-grade gliomas [21], DIPGs [22] and 
ependymomas [23], such correlations with MDM2 
expression do not exist, with very few genes passing 
the same false discovery rate criteria (FDR < 0.001) 
although this might be partially explained by PAs being 
very homogeneous entities whereas other tumor types are 
mixtures of multiple subgroups (Supplementary Figure 
Figure 3: Comparative gene expression analysis identifies specific pathways aberrantly regulated in aneuploid tumors. 
a., Aneuploidy signatures demonstrate enrichment of CNS development, cell cycle and unfolded protein binding pathways. b., Chromosomal 
mapping of the 558 genes demonstrates enrichment within chromosomes involved in aneuploid gains. c., d., Over-expression of candidates 
MDM2 c. and PLK2 (d) within the aneuploid PA subgroup (P = 1.5x10-3 and FDR adjusted P-value = 3.74x10-8 respectively; ANOVA). e., 
Correlation of MDM2 and PLK2 expression in 122 PAs with available aneuploid data (P = 0.01).
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2a-2c). Gene Ontology (GO) analysis (Supplementary 
Table 2) revealed significant GO terms corresponding to 
protein ubiquitination during ubiquitin-dependent protein 
catabolic process (GO: 42787), DNA damage response, 
signal transduction by p53 class mediator resulting in cell 
cycle arrest (GO: 6977), CNS development (GO: 7417), 
ligase activity (GO: 16874), cell cycle arrest (GO: 7050), 
cell cycle checkpoint (GO: 75) and G1 phase of mitotic 
cell cycle (GO: 80) amongst others (Supplementary 
Table 2). Utilizing the R2 chromosome mapping tool we 
mapped the 741-gene signature to respective chromosomal 
positions to determine any specific enrichment across the 
genome. In contrast to the aneuploidy signature, correlated 
genes appeared to be over-represented across chromosome 
19 (P = 4.0x10-5) and chromosome 12 (P = 7.5x10-3), but 
not any other chromosome.
BRAF-fused PA tumors comprise molecular 
entities with distinct characteristics
We analyzed various clinical and molecular 
characteristics of tumors with BRAF fusions compared 
to tumors without BRAF duplications/fusions 
(Supplementary Table 3). Tumors harbouring BRAF 
fusions/duplications were much more likely to be located 
in the infratentorial compartment (P < 0.0001), to be 
wild-type for FGFR1/BRAF mutations (P < 0.0001), 
to be euploid (P = 0.0076) and to occur in children of 
younger mean age (11.1 years compared to 19.8 years). 
No statistically significant difference in progression-
free survival was observed between patients with 
tumors positive or negative for BRAF duplication/fusion 
(Supplementary Figure 3, Supplementary Table 3), in 
keeping with data observed previously in adult PA patients 
[24].
Figure 4: MDM2 expression analysis of CNS tumors and tissues reveals high expression in aneuploid PA. a., MDM2 
expression is highest in aneuploid PA tumors (P = 4.0x10-109, ANOVA). NB = normal brain, CB = normal cerebellum, GBM = glioblastoma, 
DIPG = diffuse intrinsic pontine glioma, pHGG = pediatric high-grade glioma, EP = ependymoma, PA = pilocytic astrocytoma. b., c., d., 
MDM2 over-expression in adult patients (>18 years) (P = 1.1x10-4) b., BRAF fusion negative (P = 8.0x10-6) c. and BRAF mutant PA (P = 
9.3x10-7) d.. P-values calculated using ANOVA.
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DISCUSSION
We identify herein in a large cohort of 222 adult and 
pediatric PA located throughout the CNS, non-random 
chromosomal gains with a substantial enrichment of 
chromosomes 5, 6, 7 and 11. This aneuploidy genotype 
predominates in older patients with PA, in keeping with an 
earlier aCGH report on 44 PA samples [15]; mainly occurs 
in extra-cerebellar locations, and favors tumors that carry 
BRAF V600E but not BRAF fusions or FGFR1 mutations. 
Aneuploid tumors had increased levels of MDM2 and 
PLK2 which are involved in cell-cycle arrest and ploidy 
control and may contribute to the observed genotype. 
Importantly, aneuploidy was identified in a large number 
of older patients with PA, and may represent an additional 
molecular driver in these samples.
Whole-chromosome alterations have been 
recurrently observed in several cancer types including 
mainly leukemias and sarcomas [25, 26]. Aneuploidy in 
brain tumors is considerably less well understood and has 
been under-explored. In normal brain, aneuploidy has 
been reported as a phenomenon of the aging mammalian 
CNS (reviewed in [27]). In the developing mouse brain, it 
affects various chromosomes in 33% of embryonic cortical 
[28] or postnatal subventricular zone [29] neuroblasts. 
Notably, aneuploidy is a common feature of the developed 
CNS [30] and displays a predilection to older mice 
[31], glial cells [31], specific chromosomes (murine 
chromosomes 7, 18 and Y), and the brain cortex [31], 
which shows significant increased age-related aneuploidy 
compared to the cerebellum (which remains euploid). 
These observations are consistent with our findings that 
aneuploid tumors are enriched in older patients and non-
cerebellar areas, where BRAF fusions have the lowest 
incidence. However, we cannot formally exclude that 
some of the genomic alterations we see in adult PAs are 
not due to tumor environment differences associated with 
age, brain maturation and endocrine context. [8, 14]. 
BRAF expression and signaling is required for 
normal development of the cerebellum and hindbrain 
structures, and consequently cellular and murine studies 
of the KIAA1549-BRAF fusion show preferential growth 
selectivity in cerebellar neural stem cells [32, 33]. Within 
our dataset, aneuploid PA had significantly decreased 
frequency of BRAF fusion and mainly occurred outside 
cerebellar and hindbrain structures. They were, however, 
Figure 5: Pathway convergence leading to aneuploidy in PA.
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associated with higher frequencies of BRAF V600E, a 
genetic alteration enriched in PA located in extra-cerebellar 
regions. Interestingly, this mutation has been shown 
to induce aneuploidy through spindle anomalies and 
supernumerary centrosomes in melanocytic and melanoma 
cells [34-36]. Whether these opposing associations of 
BRAF fusion or activating mutation with aneuploidy in 
PAs is driven by subcellular expression patterns, brain-
location specific differences or MAPK-independent 
functions based on brain regions will necessitate future 
mechanistic studies. 
Aberrant regulation of developmental pathways 
may point to unique cellular origins of aneuploid PA 
tumor cells, or to developmental programs being re-
activated from inherent early mammalian developmental 
stages which demonstrate aneuploidy and are proposed to 
underlie cellular diversity of the CNS (reviewed in[27]). 
Significance of pathways involved in the unfolded protein 
response and protein ubiquitination potentially illustrates 
that aneuploid PA tumors harbor mechanisms to tolerate 
stress accompanying extra chromosomal content. Indeed, 
chromosomal gains are accompanied by substantial 
cellular stress of increased gene and protein expression[37] 
and studies in yeast demonstrate that aneuploidy causes 
proteotoxic stress, including accumulation of proteins 
more challenging to fold[38]. Aneuploidy may thus 
represent a large-scale “stress-inducible mutation”[39]. 
The triggering of the unfolded protein binding pathways 
may thus represent a mechanism that aneuploid tumors 
use to adapt and permit unadulterated growth of aneuploid 
cells (Figure 5). Alterations in the cell cycle can contribute 
to mitotic checkpoint dysregulation, continued cell 
growth and ultimately aneuploid defects[40]. Polo-like 
kinases, including PLK1 and PLK2, are critical regulators 
of cell division[41-43] and PLK2 is required for proper 
centriole duplication [42-47]. In our dataset, PLK2 was 
over-expressed in aneuploid PA tumors, and presents an 
interesting candidate for promotion and reinforcement of 
aneuploidy. Many genes differentially regulated between 
aneuploid and euploid tumors in our dataset mapped 
to commonly trisomic chromosomes, with striking 
enrichment seen across chromosome 5 (P=2.50x10-91). 
With such high frequency, chromosome 5 gains are 
not only well-tolerated in PA tumors, but may actively 
reinforce aneuploid phenotypes based on candidate 
mapping of genes including PLK2 (Figure 5). MDM2 
overexpression was also significantly associated with 
aneuploid PA and older patients. It strongly correlated with 
PLK2 expression. Mdm2 transgenic mice have increased 
age-related aneuploid defects affecting the rate of 
chromosome gain, but not loss[48, 49] similar to what is 
seen in our PA dataset. MDM2 targets p53 for degradation 
and its amplification/overexpression mimics TP53 loss[50, 
51]. The p53 regulatory pathways plays a critical role in 
limiting the progression of aneuploidy and preserving the 
nature of diploid human cells [52]. There are no reported 
TP53 alterations in PA [9, 12], but increased MDM2 
expression in aneuploid PA tumors may underlie inhibition 
of p53 function and subsequent continued growth of 
aneuploid cells. Our data show that a statistically robust 
741-gene signature, correlated with MDM2 expression, 
exists in a large dataset of 122 PA tumors, but not other 
pediatric gliomas.  GO analysis of these MDM2 correlated 
genes also points to cyclin-dependent kinases, cell cycle 
arrest and checkpoint pathways, ligase activity and CNS 
development (Supplementary Table 2). This data suggests 
a central role for MDM2 mediated programs that may 
cause and/or tolerate aneuploidy in PA (reviewed in[40]) 
(Figure 5). Moreover, maintenance of aberrant p53 
signaling through PLK2 has been identified in previous 
studies[53], further suggesting an intriguing link between 
PLK2 and MDM2 overexpression and defective p53 cell 
cycle control that may further promote aneuploidy and 
tumor formation. Future functional studies in the context 
of mediating aneuploidy in PA are needed to validate these 
concepts.
In summary, with the involvement of potential 
driving, reinforcing and tolerating mechanisms of 
aneuploidy, we describe intriguing targets for both 
future mechanistic and diagnostic/therapeutic study of 
this phenotype and its role in (adult) PA tumorigenesis. 
As these adult PA show a reduced incidence of the most 
common genetic alterations associated with pediatric PA, 
this non-random aneuploidy may be an additional genetic 
modifier in this setting, and is potentially triggered by 
aging mechanisms in glial cells of the brain and further 
promoted by the molecular alterations we identify herein.
MATERIALS AND METHODS
Sample characteristics and pathological review
All samples were obtained with informed 
consent after approval of the Institutional Review 
Board of the respective hospitals they were treated 
in, and independently reviewed by senior pediatric 
neuropathologists (S.A., A.K., V.P.C., W.P. M.H.) 
according to the WHO guidelines. Despite central review, 
we cannot exclude that a small number of samples are not 
PA but represent other low grade gliomas. Patients and 
tumor samples are described in Supplementary Table 1. 
A total of 280 patient tumors were included in our cohort, 
with copy number data available for 222 tumors, and 
KIAA1549-BRAF fusion/BRAF duplication data available 
for the majority of cases (n = 268). BRAF mutation 
status was available for 231 tumors and FGFR1 hot spot 
mutation data available for 122 samples as described 
previously. A large cohort of PA tumors (n = 126) was 
utilized for gene expression profiling, assembling data 
from newly processed samples and previously published 
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profiles of well-characterized tumor samples [9], using the 
Affymetrix HG-U133 plus 2.0 microarray (Affymetrix). 
Out of this gene expression cohort, all tumors (n = 
126) had age group information, n = 124 had BRAF 
fusion status, n = 108 had BRAF mutation status and n 
= 122 had available copy number information, with the 
techniques performed on individual samples described 
in Supplementary Table 1. Gene expression data was 
compared with other published datasets of glioblastoma 
(n = 84), pediatric high-grade glioma (n = 53), diffuse-
intrinsic pontine glioma (DIPG) (n = 37), ependymoma 
(n = 83) normal brain [54] and normal cerebellum [55] 
as controls. Age≥18 is classified as adult. Both adult and 
pediatric tumors were obtained from the London/Ontario 
Tumor Bank, and from collaborators in Canada, Hungary, 
the United Kingdom and Germany. 
RNA and DNA extraction
RNA and DNA extraction methods for previously 
published cohorts are described in [6, 7, 9, 10, 15-17]. 
RNA and DNA were isolated from a subset of additional 
tumors using the Qiagen RNeasy Lipid Tissue Mini kit, 
Qiagen QIAmp/DNeasy DNA Mini kits respectively 
according to instructions of the manufacturer. 
KIAA1549-BRAF fusion screening
BRAF fusion status for previously described cohorts 
was determined as demonstrated in [6, 7, 9, 10, 16, 17]. 
RT-PCR to detect the three most common KIAA1549-
BRAF fusion transcripts was performed for a subset of 
additional samples as previously described [6].
DNA copy number analysis
For SNP analysis, DNA (250 ng) from PA samples 
was assayed with the HumanOmni1-Quad & Human 
Omni2.5 genotyping beadchip platforms according to 
the recommendations of the manufacturer (Illumina, 
San Diego, CA, USA). For a subset of formalin-fixed 
paraffin-embedded (FFPE)-derived DNA samples (n = 
13, Supplementary Table 1), DNA was first rescued with 
the Illumina FFPE restore assay kit (Illumina, Inc) and 
subsequently hybridized to the Illumina Omni2.5-8 v1.0 
chip. These BeadChip platforms enable whole-genome 
genotyping of respectively over 1,140,419 (Omni1-Quad) 
and 2,379,855 (Omni2.5) tagSNP markers derived from 
the 1,000 Genomes project, all three HapMap phases, 
and recently published studies. Image intensities were 
extracted using Illumina’s BeadScan software. Data for 
each BeadChip were self-normalized using information 
contained within the array. Copy number data was also 
included from previously published datasets utilizing SNP 
arrays and array-based comparative genomic hybridization 
(aCGH) [6, 7, 10, 15, 16] with new analyses incorporating 
whole chromosome copy number profiling from 450K 
methylation arrays (Illumina) utilizing the R package 
‘conumee’ (http://www.bioconductor.org/packages/
release/bioc/html/conumee.html) essentially as described 
[56] and applied to published data [17]. In total, whole 
chromosomal copy number data was combined to yield 
a dataset of 222 tumors with numerical chromosome 
information to assess ploidy status.
Gene expression profiling and analysis
A large dataset of PA tumors (n = 126) [9] was 
combined for gene expression profiling using the online 
R2: microarray analysis and visualization platform (http://
r2.amc.nl). Ploidy status information was available for 
the majority of tumors with Affymetrix HG-U133 plus 
2.0 gene expression data (n = 122) and was compared 
on this basis and on the basis of other molecular and 
clinical variables including BRAF fusion (data available 
for n = 124 tumors), BRAF mutation (n = 108 tumors) 
and age group (n = 126 tumors) through differential 
expression analysis using ANOVA at a false discovery 
rate (FDR) cut-off of < 0.001 (as are displayed in Figure 
2c, Figure 3 and Figure 4). A list of 558 genes passing 
FDR criteria were kept and utilized for further analyses of 
the aneuploid phenotype. Gene Ontology (GO) analysis 
was performed for these 558 differentially expressed 
genes utilizing the R2 database tool and presented in 
Figure 3a. Gene expression of MDM2 and PLK2 was 
assessed using absolute correlation analysis with results 
displayed in Figure 3e. Based on its elevated expression 
in aneuploid PA tumors compared with other brain tumors 
and normal tissue, MDM2 was pursued for additional 
correlation analyses. We investigated genes correlating 
(absolute correlation) with the expression of MDM2 at a 
stringent false discovery rate (FDR) corrected criterion 
of < 0.001, which resulted in 741 robust combinations 
used for further Gene Ontology (GO) analysis and 
chromosome mapping in the dataset of 122 PA tumors 
profiled for aneuploidy. In control glioma and normal 
brain datasets detailed above, absolute correlation with 
identical FDR < 0.001 was calculated for genes correlating 
with MDM2. Representative heatmaps using transformed 
z-scores illustrating correlated signatures are displayed in 
Supplementary Figure 2a-2c and were generated utilizing 
the R2 database tool. Exonic level expression of exons 
1a, 1b and 2 of MDM2 from previously published RNA-
sequencing data [9] was assessed to determine ratios of 
promoter 1 (P1) and P2 usage in a subset of PA tumors 
with available data (n = 69).
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MDM2 SNP 309 sanger sequencing
Sanger sequencing of the MDM2 promoter 
SNP 309 was performed on 201 tumors using 
HotStart FastTaq KIT (Kapa) using forward primer: 
5’-TGGTGAGGAGCAGGTACTGG-3’ and reverse 
primer: 5’-CGGAACGTGTCTGAACTTGA-3’ with the 
following PCR cycling conditions: 1 cycle of 1 minute at 
96°C, 33 cycles of 10 seconds at 96°C, 5 seconds at 58°C 
and 1 second at 72°C followed by 1 cycle at 72°C for 30 
seconds.
Quantitative RT-PCR determination of MDM2 
expression levels
Quantitative determination of MDM2 expression 
levels was performed utilizing the Ssofast Evagreen 
kit (BioRad) with standard conditions indicated by the 
manufacturer at an annealing temperature of 58°C on 
the Roche LightCycler 480 (Roche) in a subset of 22 PA 
samples. Cycle threshold (Ct) values were normalized to 
β-actin (ACTB) and a calibrator normal brain sample with 
wild-type (TT) MDM2 SNP 309 genotype using the 2-ΔΔCt 
method. The following primers were used:
5’-TCTCAAGCTCCGTGTTTGGTCAGT-3’, 
MDM2 forward
5’-ACCTTGCAACAGCTGCAGATGAAC-3’, 
MDM2 reverse
5’-GGCACCCAGCACAATGAAGATCAA-3’, 
β-actin forward 
5’TAGAAGCATTTGCGGTGGACGATGGA-3’. β-actin 
reverse
Statistical analyses
Contingency (Fisher’s Exact Test), unpaired, 
two-tailed t-test comparisons and one-way ANOVA 
were performed utilizing GraphPad Prism to determine 
P-values. ANOVA, absolute correlation and multiple test 
correction using false discovery rate (FDR) and Gene 
Ontology (GO) calculations were performed within R2. 
Kaplan-Meier analyses were performed within GraphPad 
Prism for tumors with available data: aneuploidy (n = 
193), BRAF fusion (n = 233), BRAF mutation (n = 196), 
brain location (n = 235).
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